GlassScriptPhysician profile
Amal Elhaj
NPI 1144647041
$3,899.39
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $295 · 2021: $1,509 · 2022: $1,572 · 2023: $509 · 2024: $14.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $551.99 | 2020-2023 | |
| Abbvie INC. | $338.98 | 2021-2023 | Qulipta, Botox, Ubrelvy |
| Emd Serono, INC. | $249.94 | 2021-2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $246.34 | 2020-2023 | Austedo |
| Ucb, INC. | $244.22 | 2021-2023 | Fintepla, Nayzilam |
| Biogen, INC. | $174.85 | 2021-2022 | |
| Genentech USA, INC. | $173.65 | 2021-2022 | |
| Eisai INC. | $166.69 | 2021-2023 | |
| Sk Life Science, INC. | $166.12 | 2021-2023 | |
| Aquestive Therapeutics, INC. | $122.59 | 2020-2022 | |
| Lundbeck LLC | $121.25 | 2020-2023 | Vyepti |
| Sunovion Pharmaceuticals INC. | $110.96 | 2021-2022 | |
| Acorda Therapeutics, INC | $108.75 | 2020-2023 | Inbrija |
| Lilly USA, LLC | $99.44 | 2021-2023 | Amyvid, Reyvow, Emgality |
| Alexion Pharmaceuticals, INC. | $90.12 | 2020-2023 | Ultomiris |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amal Elhaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.